AgomAb Therapeutics NV

AGMB·NasdaqGS
Compare
9.09+0.01 (+0.11%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close9.08
Open9.08
Day range9.059.64
52-week range7.9717.82
Off day high−5.71%
Off 52-week high−48.99%
Volume61.97K
Avg. volume (3M)138.87K
Market cap447.66M
EPS (TTM)-2.08
Forward P/E-4.44
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)—
Shares outstanding49.25M
Short interest—
Earnings date—
Analyst target—
Profit margin—

Against its peers

Compare in full ›
AGMB AVBP IMRX ACRS GPCR CRVS
Market cap 447.66M 811.61M 249.73M 529.92M 1.71B 845.42M
P/E (TTM) — — — — — —
Forward P/E -4.4 -4.2 -3.1 -4.6 -11.3 -9.4
Price/book 3.6 2.2 1.3 4.0 1.3 3.8
Dividend yield — — — — — —
1-year change −37.95% −17.70% −35.83% +88.48% −15.40% +47.96%
Today +0.11% −1.61% −2.03% −6.01% −6.38% −4.47%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All AGMB news ›
Stock Titan·

AgomAb Therapeutics director buys 5,000 shares

Direct holdings reached 15,000 common shares after David R. Epstein's October 8, 2026 purchase. No Rule 10b5-1 plan is reported in the Form 4. - [Form 4] AgomAb Therapeutics NV Insider Trading Activity AgomAb Therapeutics director buys…

From articles in the 4Search news index.

In the news

3mentions in 30 days
3with it in the headline
Mixedsentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use.